Background: Survival and prognostic factors for thin melanomas have been relatively little studied in population-based settings. This patient group account for the majority of melanomas diagnosed in western countries today and better prognostic information is needed.
Introduction
Since 1990, the Swedish Melanoma Study Group (SMSG) has prospectively gathered data concerning diagnosis, treatment, and follow-up on all Swedish cases of Cutaneous Malignant Melanoma (CMM). The data is collected and registered at the six regional oncology centres in Sweden and transferred to the national database, the Swedish Melanoma Register (SMR) in Linköping. A first report on CMM in Sweden (1990 Sweden ( -1999 has been published 1 . Since a majority of melanomas diagnosed in many countries are thin (≤1 mm), further studies concerning this large subgroup of melanoma patients are motivated. In the American Joint Committee on Cancer (AJCC) 2009 the mitotic index has been added as prognostic factor 2 and the research of other new factors are in progress 3, 4 . However, there are a few studies from Germany, Australia, and USA [4] [5] [6] [7] [8] [9] [10] that indicate that the previous AJCC 2002 melanoma staging 11 could be further refined for thin melanomas by simply combining the traditional prognostic factors in alternative ways. Due to its size and being population-based, the SMR is ideal when exploring new risk stratifications in thin melanomas. The aim of this study is to use established prognostic factors such as ulceration, tumour thickness and Clark's level of invasion for risk stratification of T1 cutaneous melanoma.
Materials and methods
During the time period 1990-2008, 30 157 patients with primary CMMs were reported to the SMR.
The mean annual coverage rate was 97% (range 93-99%) compared to the Swedish National Cancer
Register, to which reporting of all new malignancies is mandated by Swedish law 12 . The current registration is population-based and nationwide. All cases are registered with a unique patient identification-number which facilitates record linking.
From the 30 157 patients, 13 488 (44·7%) patients had T2-T4 tumours and 1183 (3·9%) patients had no information about tumour thickness and were both excluded. 13 and the cause of death of patients aged 90+ could be uncertain due to co-morbidities. ALM type and melanomas localised to palm/subungual were excluded in order to avoid potential errors in the measure of tumour thickness.
The following clinical variables were studied: age at diagnosis, gender and tumour site.
Histopathological characteristics of the primary tumour including tumour thickness, Clark's level of invasion, presence/absence of ulceration and histogenetic type were registered. Histopathological data was reported directly from the pathology department's database. Data on cause of death until December 31, 2009 was obtained from the Swedish Cause of Death Register and was used to calculate the melanoma-specific mortality rate. Patients having a second CMM during the study period were censored at the point in time of the second diagnosis.
Excision margin used was 1 cm except for a small cohort of CMM with tumour thickness ≥0·8 mm operated 1990-1991 with 2 or 5 cm wide excision margins due to an ongoing study at that time 14 .
According to the Swedish National Guidelines for CMM, sentinel node biopsy was not recommended for melanomas ≤1 mm before 2007. However, sentinel node biopsies were performed in 91 cases with positive results in 5. Shave biopsies and other similar procedures are not recommended by the Swedish National Guidelines for CMM. The results from the Cox-analyses combined with results of melanoma-specific mortality rates from Kaplan-Meier were used to identify prognostic subgroups. In the text and the tables, 95% CI are shown in parentheses. All statistical analyses were performed by using SAS 9·2.
Statistical analysis

Results
During a median follow up time of 6·6 years (range 0-20 years), 311 (2·4%) patients died from their melanoma. Within the follow-up period, 1731 (13·3%) patients died of causes other than melanoma.
There were 314 patients (2·4%) with a second melanoma diagnosis within the study period. An additional 27 (0·2%) patients were censored due to emigration. The median age at diagnosis was 58 years, the median thickness was 0·6 mm and 55% of the patients were women.
-Insert Table 1 about hereMelanoma-specific mortality rate data from the SMR are presented in Table 1 . The overall 10-and 15-year melanoma-specific mortality rates were 3·4% (3·0-3·8%) and 4·4% (3·9-5·0%), respectively.
The melanoma-specific mortality rates for the very thin (≤0·5 mm) compared to the thickest (>0·75 mm)
varied from 1·9% (1·0-3·7%) to 6·6% (5·6-7·8%) at 10 years and from 3·2% (1·6-6·4%) to 8·9% (7·5-10·6%) at 15 years.
In univariate Cox analysis of mortality, the three most dominant factors were tumour thickness (χ2=103·2, df=2, p<0·0001), ulceration (χ2=83·2, df=1, p<0·0001) and Clark's level of invasion (χ2=74·6, df=2, p<0·0001) ( Table 2 ). The largest effect estimates were observed for melanoma thickness >0·75 mm versus ≤0·5 mm group (HR: 4·7, 95% CI 3·4-6·5), ulceration versus non-ulceration (HR: 4·5, 95% CI 3·3-6·2) and Clark level IV-V versus Clark level II (HR: 4·4, 95% CI 3·0-6·3).
-Insert Table 2 about here-
In the multivariate Cox analysis ulceration (χ2=46·7, df=1, p<0·0001), tumour thickness (χ2=29·4, df=2, p<0·0001) and Clark's level of invasion (χ2=12·3, df=2, p=0·002) were still the most important prognostic factors ( Table 2 ). The highest hazard ratios were observed for ulceration versus non-ulceration (HR: 3·2, 95% CI 2·3-4·4), melanoma thickness >0·75 mm versus ≤0·5 mm group (HR: 2·8, 95% CI 1·9-4·1) and Clark IV-V versus Clark II (HR: 2·1, 95% CI 1·4-3·3). In a further multivariate Cox analysis of all potential interaction effects (data not shown), there was a significant interaction between tumour thickness and ulceration (χ2=6·9, df=2, p=0·03). This interaction indicates that tumour thickness was a less important prognostic factor when the melanoma was ulcerated (HR: 0·8 for >0·75 mm versus ≤0·5 mm group, 95% CI 0·3-1·9) compared with non-ulcerated melanomas (HR: 3·5 for >0·75 mm versus ≤0·5 mm group, 95% CI 2·3-5·4).
The multivariate analysis confirmed the great influence of ulceration, tumour thickness and Clark's level of invasion on melanoma-specific mortality. Thus, we estimated the 10-year melanoma-specific mortality rate in each patient group defined according to these three tumour characteristics (Table 3 ).
-Insert Table 3 about here-
Using the results presented in Table 3 we divided the T1-melanomas into three risk groups: a low risk group of non-ulcerated Clark II-III ≤0·75 mm melanomas (67·9% of T1 cases) with a 10-year melanoma-specific mortality rate of 1·5% (1·2-1·9%); an intermediate risk group of melanomas that were non-ulcerated >0·75 mm; or non-ulcerated Clark IV-V; or ulcerated Clark II ≤0·75 mm (28·6% of T1 cases) with a 10-year melanoma-specific mortality rate of 6·1% (5·0-7·3%); and a high risk group consisting of all ulcerated T1 melanomas except Clark II ≤0·75 mm (3·5% of T1 cases) with a 10-year melanoma-specific mortality rate of 15·6% (11·2-21·4%). Fig.1 shows the cumulative melanoma-specific mortality for the three risk groups.
-Insert fig.1 about here-
Discussion
The authors analysed all melanomas registered in the SMR 1990-2008, a large unselected material representing the total Swedish population. The benefits of using large population-based materials are evident from a review of published survival data concerning thin melanomas. We have transformed and used this data as 10-year melanoma-specific mortality rates. The data from the current study (SMR), Queensland Cancer Registry (QCR) 5 , Surveillance, Epidemiology, and End Results (SEER) 6, 7 and New South Wales (NSW) 10 can be categorised as population-based while other cohorts are either multi-or single institution data; AJCC 2002 11, 16 , AJCC 2009 2 , the German melanoma register (CMMR) 8 ,
Pennsylvania pigmented lesion group (PLG) 6 and Sydney melanoma unit (SMU) 10 .
-Insert Table 4 SMR data indicate that the original thickness cut off value (0·76 mm) defined by Breslow 18 still seems to have a significant impact on the prognosis of T1 melanoma. Clark et al. 19 demonstrated that almost all melanomas ≤0·75 mm or of Clark level II were of radial growth phase and that these melanomas rarely showed mitoses. They found no metastases in that group compared with melanomas with a vertical growth phase 19 . A thickness of ≤0·75 mm and Clark level II might thus be a good approximation of the radial growth phase. The 10-year melanoma-specific mortality rates for melanomas in SMR, QCR, NSW, SEER, CMMR and PLG for melanomas >0·75 mm are very similar (6·1-8·0%).
In all the reviewed studies except that of CMMR, ulceration is a poor prognostic sign. Unfortunately the large population-based QCR had no information on ulceration.
To further validate our data, we divided the data into nine groups from the expanded AJCC described by Gimotty 6 . Only minor differences were found in comparison with SEER data: head/neck tumours in SEER have higher mortality than in the SMR (SEER groups 3-4) and also SEER finds gender differences that are not apparent in the SMR (SEER group 5-6).
-Insert Table 5 In all the analyses from the SMR, patients were censored at the time point of a new melanoma diagnosis, thus eliminating the risk of a second melanoma being the underlying risk for cause of death from melanoma. However this methodology was not used in the other studies. Omitting censoring at the second melanoma diagnosis however, changed the SMR results only marginally; the 10-year melanomaspecific mortality rate increased by 0·3% (from 3·4% to 3·7%) in the total study cohort and there was no alteration regarding the outcome with respect to prognostic factors. In the SMR, eight cases of Clark level V were used in the multivariate analysis and this may indicate that these patients could have had thicker melanomas than what was actually registered. Only two of these were classified into the high risk group, one of whom died from the melanoma. Excluding the cases with Clark level V did not change the results in the multivariate Cox analysis. Five cases with positive sentinel node studies were identified, but none of those patients were classified into the high risk group. In the multivariate Cox analysis for T1, we tested two alternative ways of including tumour thickness. We tested if the Cox-model was improved by using four different tumour groups or by using a continuous thickness variable. None of these models added significant additional information (p-values 0·32 and 0·04 respectively) and we therefore choose to stay with the three group model. Tumour thickness with three groups is also the most common way of dealing with this variable in other studies and this facilitates comparisons.
It is important to have the possibility to give patients with thin melanoma more accurate prognostic information. In Sweden thin melanomas constitute more than 50% (even higher for females and younger patients) of all melanomas. The prognosis is very good in average compared to other stages of melanoma and other cancer types, but we found a mortality range of 1-25% showing the importance of using prognostic factors. In the SMR, the high risk group (3·5% of T1) accounts for 15% of all melanoma deaths, and the intermediate group (28·6% of T1) accounts for 51% of all melanoma deaths. Using the old AJCC-2002 classification on SMR data, 12% of the patients were classified into T1b accounting for 31% of melanoma deaths. Our findings thus predict 66% of all melanoma deaths compared to 31% from conventional T1b.
In conclusion, using a population-based melanoma register and combining ulceration, tumour thickness and Clark's level of invasion three distinct prognostic subgroups were identified. Meta-analyses of population-based melanoma registers may be a method to further improve the risk stratification in this patient group. Cumulative mortality (95% CI): 
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